

## I CLAIM:

1. A use of an active substance for producing medication to treat dementia disorders and/or depression, the substance comprising:  
  
means for increasing a dopamine concentration in a synaptic gap of brain nerve cells, and  
an anilide group local anaesthetic or a derivative thereof.
2. The use of claim 1, wherein mepivacaine is said anilide group local anaesthetic or said derivative thereof.
3. The use of claim 2, wherein said mepivacaine is applied in a daily dose of 30mg to 60mg.
4. The use of claim 1, wherein lidocaine is said anilide group local anaesthetic or said derivative thereof.
5. The use of claim 4, wherein said lidocaine is applied in a daily dose of up to 150g.
6. The use of claim 1, wherein bupivacaine is said anilide group local anaesthetic or said derivative thereof.
7. The use of claim 6, wherein said bupivacaine is applied in a daily dose of up to 150mg.
8. The use of claim 1, wherein butanilicaine is said anilide group local anaesthetic or said derivative thereof.

9. The use of claim 1, wherein tholycaine is said anilide group local anaesthetic or said derivative thereof.
10. The use of claim 1, wherein etidocaine is said anilide group local anaesthetic or said derivative thereof.
11. The use of claim 1, wherein ropivacaine is said anilide group local anaesthetic or said derivative thereof.
12. The use of claim 11, wherein said ropivacaine is applied in a dose of 0.2mg to 4mg.
13. The use of an agent for producing medication for treatment of dementia disorders and/or depression according to claim 1, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells contains LevoDopa.
14. The use of claim 13, wherein said LevoDopa is applied in a daily dose of 200mg to 600mg.
15. The use of claim 13, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells additionally contains bromocriptine.
16. The use of claim 15, wherein said bromocriptine is applied in a daily dose of 0.1mg to 10mg.
17. The use of claim 13, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells additionally contains selegiline.

18. The use of claim 17, wherein said selegiline is applied in a daily dose of 4mg to 20mg.
19. The use of claim 18, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells additionally contains amantadine.
20. The use of claim 19, wherein said amantadine is applied in a daily dose of 100mg to 400mg.
21. The use of claim 13, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells additionally contains pergolide mesilate.
22. The use of claim 21, wherein said amantadine is applied in a daily dose of 2mg to 8mg.
23. The use of claim 22, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells additionally contains tolcapone.
24. The use of claim 23, wherein said tolcapone is applied in a daily dose of 100mg to 400mg.
25. The use of claim 13, wherein said means for increasing said dopamine concentration in said synaptic gap of said brain nerve cells additionally contains piracetam.
26. The use of claim 25, wherein said piracetam is applied in a daily dose of 1,000mg to 4,000mg.